Breaking Finance News

CRITICAL OUTCOME T COM NPV (NASDAQ:COTQF) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded CRITICAL OUTCOME T COM NPV (NASDAQ:COTQF) to Hold in a statement released on 11/28/2016.

Boasting a price of $0.41, CRITICAL OUTCOME T COM NPV (NASDAQ:COTQF) traded 0.00% even on the day. With the last stock price close up 85.97% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. CRITICAL OUTCOME T COM NPV has recorded a 50-day average of $0.25 and a two hundred day average of $0.22. Volume of trade was down over the average, with 0 shares of COTQF changing hands under the typical 11,432

Performance Chart

CRITICAL OUTCOME T COM NPV (NASDAQ:COTQF)

With a total market value of $0, CRITICAL OUTCOME T COM NPV has with a one year low of $0.16 and a one year high of $0.69 .

Brief Synopsis About CRITICAL OUTCOME T COM NPV (NASDAQ:COTQF)

Critical Outcome Technologies Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The companyÂ’s proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Its lead compound is COTI-2, a novel small molecule activator of misfolded mutant p53 proteins, which is in Phase I clinical trial for the treatment of gynecologic cancers, including ovarian, cervical, and endometrial cancers. The company also develops drug candidates for the treatment of acute myelogenous leukemia, colorectal cancer, small cell lung cancer, multiple sclerosis, and AlzheimerÂ’s disease; and HIV integrase inhibitors. Critical Outcome Technologies Inc. was founded in 1999 and is based in London, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *